Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MPO | P05164 | 2/20 | 0.40 |
| ▸ | ACHE | P22303 | 1/20 | 0.35 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.35 |
| ▸ | F2 | P00734 | 3/20 | 0.34 |
| ▸ | PPARA | Q07869 | 2/20 | 0.34 |
| ▸ | BACE1 | P56817 | 1/20 | 0.33 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.33 |
| ▸ | FLT3 | P36888 | 1/20 | 0.33 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.33 |
| ▸ | CCNE2 | O96020 | 1/20 | 0.33 |
| ▸ | CDK4 | P11802 | 1/20 | 0.33 |
| ▸ | CCND1 | P24385 | 1/20 | 0.33 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.33 |
| ▸ | CDK2 | P24941 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 2/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | ERN1 | O75460 | 1/20 | 0.32 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.32 |
| ▸ | PTGES | O14684 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10076613 | 0.81 | GRM2 (0.37) | ACHEHRH4CYP1A2ALDH1A1 | |
| SCHEMBL7427955 | 0.77 | MPO (0.46) | MPOACHEHRH4F2BACE1 | |
| SCHEMBL29487338 | 0.77 | MPO (0.41) | MPOACHEHRH4F2BACE1 | |
| SCHEMBL3306872 | 0.77 | MPO (0.41) | MPOACHEHRH4F2BACE1 | |
| SCHEMBL17250761 | 0.75 | ALDH1A1 (0.49) | CCNE2CDK4CCND1CCNE1CDK2 | |
| SCHEMBL176103 | 0.75 | MEN1 (0.33) | MPOACHEF2MEN1KMT2A | |
| SCHEMBL5498929 | 0.74 | HRH4 (0.50) | MPOACHEHRH4F2BACE1 | |
| SCHEMBL15054414 | 0.74 | MPO (0.46) | MPOACHEHRH4F2ERN1 | |
| SCHEMBL161307 | 0.71 | NT5E (0.32) | CYP2C19PTGES | |
| SCHEMBL3503833 | 0.70 | MPO (0.40) | MPOACHEBACE1HTTCYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2590960-B1 | HETEROCYCLIC ANTIVIRAL COMPOUNDS | HOFFMANN LA ROCHE (CH) | 2014-06-11 | — | — | EP | disclosed |
| US-8734777-B2 | Heterocyclic antiviral compounds | ROCHE PALO ALTO LLC (US) | 2014-05-27 | — | — | US | disclosed |
| US-20130209397-A1 | HETEROCYCLIC ANTIVIRAL COMPOUNDS | ROCHE PALO ALTO LLC (US) | 2013-08-15 | — | — | US | disclosed |
| CN-103068819-A | Heterocyclic antiviral compounds | HOFFMANN LA ROCHE | 2013-04-24 | — | — | CN | disclosed |
| CN-102971305-A | Heterocyclic antiviral compounds | HOFFMANN LA ROCHE | 2013-03-13 | — | — | CN | disclosed |
| US-8329712-B2 | Heterocyclic antiviral compounds | ROCHE PALO ALTO LLC (US) | 2012-12-11 | — | — | US | disclosed |
| US-20120009144-A1 | HETEROCYCLIC ANTIVIRAL COMPOUNDS | ROCHE PALO ALTO LLC (US) | 2012-01-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130209397-A1 | HETEROCYCLIC ANTIVIRAL COMPOUNDS | EIF2AK2, HCCS, MAVS | MPO 420/4885ACHE 2947/4885HRH4 2058/4885 |
| US-20120009144-A1 | HETEROCYCLIC ANTIVIRAL COMPOUNDS | EIF2AK2, HCCS, RNASE1 | MPO 488/4885ACHE 2881/4885HRH4 1597/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.